Novan Completes Enrollment in B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum
February 01, 2021 08:05 ET
|
Novan, Inc.
– Topline data on track for targeted readout before the end of Q2 2021 – – SB206, if approved, has the potential to meet an important need for the treatment of molluscum, an area with no current...
Novan Regains Compliance with Nasdaq Minimum Bid Price Requirement
January 29, 2021 16:05 ET
|
Novan, Inc.
MORRISVILLE, N.C., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it has received written notice from The Nasdaq Stock Market LLC...
Novan Provides Enrollment Update and Announces New Corporate Headquarters
January 19, 2021 09:00 ET
|
Novan, Inc.
– B-SIMPLE4 pivotal Phase 3 study in molluscum contagiosum reaches 90% enrollment with topline data targeted for Q2 2021 – – Company secures new location to serve as corporate headquarters and to...
Novan to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference
January 08, 2021 09:00 ET
|
Novan, Inc.
MORRISVILLE, N.C., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that Paula Brown Stafford, President and Chief Executive Officer of Novan,...
Novan Engages Catalent to Develop Intranasal Formulation of Berdazimer Sodium for COVID-19 Program
December 21, 2020 09:00 ET
|
Novan, Inc.
– Catalent has a proven track record of accelerating molecules from early development through commercial manufacturing – – Company targets initiating preclinical Investigational New Drug (IND)...
Novan Exceeds 60% Enrollment in B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum
December 15, 2020 09:00 ET
|
Novan, Inc.
– Completion of patient enrollment targeted for Q1 2021 with readout of topline results targeted for Q2 2021 – – SB206, if approved, has the potential to meet an important need for the treatment of...
Novan Receives Approval to Transfer to Nasdaq Capital Market
November 04, 2020 07:30 ET
|
Novan, Inc.
– Trading on Nasdaq Capital Market is expected to begin on November 5, 2020 – – Company receives additional 180-day grace period, until May 3, 2021, to satisfy the $1.00 bid price requirement to...
Novan Reports Third Quarter 2020 Financial Results and Provides Corporate Update
October 30, 2020 07:30 ET
|
Novan, Inc.
– Lead product candidate, SB206 currently being evaluated in B-SIMPLE4 pivotal Phase 3 study in molluscum contagiosum with topline data targeted for Q2 2021 – – First to demonstrate antiviral effect...
Novan to Present at the Virtual Investor KOL Roundtable
October 21, 2020 09:00 ET
|
Novan, Inc.
MORRISVILLE, N.C., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that members of management will participate in the Virtual Investor KOL...
Novan’s NITRICIL™ Technology Shows In Vitro Antiviral Effect Against SARS-CoV-2 in Human Airway Infection Model
October 14, 2020 07:00 ET
|
Novan, Inc.
- First demonstration of antiviral effect of nitric oxide-based medicine against SARS-CoV-2 in an in vitro model that mimics the human airway epithelium - Company believes preclinical results...